The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Crossroads in GDNF therapy for Parkinson's disease
Abstract
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Self-citation
Cited by
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Decressac, M., Kadkhodaei, B., Mattsson, B., Laguna, A., Perlmann, T., & Björklund, A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004676 · Cited by 290
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Point source concentration of GDNF may explain failure of phase II clinical trial
SALVATORE, M., AI, Y., FISCHER, B., ZHANG, A., GRONDIN, R., ZHANG, Z., GERHARDT, G., & GASH, D. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.015 · Cited by 260
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease
Rafii, M. S., Baumann, T. L., Bakay, R. A. E., Ostrove, J. M., Siffert, J., Fleisher, A. S., Herzog, C. D., Barba, D., Pay, M., Salmon, D. P., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.004 · Cited by 223
Slevin, J. T., Gash, D. M., Smith, C. D., Gerhardt, G. A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R., & Young, A. B. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.4.614 · Cited by 173
Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
Garbayo, E., Montero-Menei, C. N., Ansorena, E., Lanciego, J. L., Aymerich, M. S., & Blanco-Prieto, M. J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.12.010 · Cited by 150
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease
Marella, M., Seo, B. B., Nakamaru-Ogiso, E., Greenamyre, J. T., Matsuno-Yagi, A., & Yagi, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001433 · Cited by 116
“Unfortunately, these agents are known to be only moderately effective for PD [2–5].”
BackgroundKim, S. R., Kareva, T., Yarygina, O., Kholodilov, N., & Burke, R. E. (2012) · Molecular Therapy · doi:10.1038/mt.2011.213 · Cited by 107
Bartus, R. T., & Johnson, E. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.027 · Cited by 97
Michel, T. M., Frangou, S., Camara, S., Thiemeyer, D., Jecel, J., Tatschner, T., Zoechling, R., & Grünblatt, E. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.06.001 · Cited by 78
Herzog, C. D., Dass, B., Gasmi, M., Bakay, R., Stansell, J. E., Tuszynski, M., Bankiewicz, K., Chen, E.-Y., Chu, Y., Bishop, K., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.170 · Cited by 72
Herzog, C. D., Bishop, K. M., Brown, L., Wilson, A., Kordower, J. H., & Bartus, R. T. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0037-z · Cited by 29
Metadata
- Authors
- Sherer, T. B., Fiske, B. K., Svendsen, C. N., Lang, A. E., & Langston, J. W.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2006-02
- Volume
- 21
- Issue
- 2
- Pages
- 136-141
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1997631088
- Cited by
- 172
- References
- 2
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.